See more : Tiger Oil and Energy, Inc. (TGRO) Income Statement Analysis – Financial Results
Complete financial analysis of Kubota Pharmaceutical Holdings Co., Ltd. (4596.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kubota Pharmaceutical Holdings Co., Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Holcim Philippines, Inc. (HCPHY) Income Statement Analysis – Financial Results
- American Shipping Company ASA (ASCJF) Income Statement Analysis – Financial Results
- Asia Financial Holdings Limited (AIFIF) Income Statement Analysis – Financial Results
- Olam Group Limited (OLMIY) Income Statement Analysis – Financial Results
- Real Luck Group Ltd. (LUKEF) Income Statement Analysis – Financial Results
Kubota Pharmaceutical Holdings Co., Ltd. (4596.T)
About Kubota Pharmaceutical Holdings Co., Ltd.
Kubota Pharmaceutical Holdings Co., Ltd. develops portfolio of drugs and devices worldwide. Its product pipeline comprises emixustat hydrochloride, which is in Phase III clinical stage used for the treatment of stargardt disease, and Phase II clinical stage used for the treatment of proliferative diabetic retinopathy. The company is also developing remote retinal monitoring device patient-based ophthalmology suite, that includes home-based miniature and NASA high-res version optical coherence tomography devices; and wearable device for myopia control. The company was founded in 2002 and is based in Tokyo, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 39.89M | 8.25M | 0.00 | 37.79M | 0.00 |
| Cost of Revenue | 98.93M | 5.82M | 59.24M | 0.00 | 45.95M |
| Gross Profit | -59.05M | 2.43M | -59.24M | 37.79M | -45.95M |
| Gross Profit Ratio | -148.03% | 29.48% | 0.00% | 100.00% | 0.00% |
| Research & Development | 788.79M | 1.51B | 2.04B | 1.97B | 2.76B |
| General & Administrative | 0.00 | 601.29M | 603.91M | 606.27M | 532.08M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 633.00M | 601.29M | 603.91M | 606.27M | 532.08M |
| Other Expenses | 0.00 | 15.21M | -24.82M | -4.77M | -10.14M |
| Operating Expenses | 1.33B | 2.04B | 2.58B | 2.52B | 3.29B |
| Cost & Expenses | 1.43B | 2.05B | 2.58B | 2.52B | 3.29B |
| Interest Income | 0.00 | 18.46M | 11.24M | 67.80M | 218.12M |
| Interest Expense | 0.00 | 11.56M | 18.17M | 16.40M | 24.82M |
| Depreciation & Amortization | 87.16M | 58.97M | 59.24M | 45.38M | 45.95M |
| EBITDA | -1.39B | -1.95B | -2.54B | -2.38B | -3.03B |
| EBITDA Ratio | -3,492.54% | -23,568.80% | 0.00% | -6,287.10% | 0.00% |
| Operating Income | -1.39B | 2.04B | 2.58B | -2.48B | -3.29B |
| Operating Income Ratio | -3,493.65% | 24,691.30% | 0.00% | -6,573.98% | 0.00% |
| Total Other Income/Expenses | -96.09M | 95.09M | 27.55M | 46.62M | 183.16M |
| Income Before Tax | -1.49B | -2.02B | -2.62B | -2.44B | -3.11B |
| Income Before Tax Ratio | -3,734.56% | -24,423.38% | 0.00% | -6,450.60% | 0.00% |
| Income Tax Expense | 0.00 | -4.04B | -5.18B | 63.02M | -39.67M |
| Net Income | -1.49B | -2.02B | -2.62B | -2.44B | -3.07B |
| Net Income Ratio | -3,734.56% | -24,423.38% | 0.00% | -6,450.60% | 0.00% |
| EPS | -26.79 | -40.92 | -57.46 | -56.90 | -71.57 |
| EPS Diluted | -26.79 | -40.92 | -57.46 | -56.90 | -71.57 |
| Weighted Avg Shares Out | 55.59M | 49.27M | 45.54M | 42.84M | 42.84M |
| Weighted Avg Shares Out (Dil) | 55.59M | 49.27M | 45.54M | 42.84M | 42.84M |
Source: https://incomestatements.info
Category: Stock Reports